Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications.
Current Price
$54.12
-1.02%Xenon Pharmaceuticals Inc (XENE) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Xenon Pharmaceuticals Inc's financial performance and position as a Healthcare company.
Trailing twelve-month (TTM) revenue is $0.00. Gross profit (TTM) is $0.00. EBITDA is $-381.35M. Earnings per share (EPS) is $-4.36. The P/E ratio is -11.75. Market capitalization is $4.50B.
Free cash flow (FCF) is $-279.92M. Weighted average cost of capital (WACC) is 10.00%.
Historical revenue data covers 7 years from FY19 to FY25. Net income history spans 7 years. Free cash flow and capital expenditure data spans 7 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.
Use Xenon Pharmaceuticals Inc's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.
